Interim Methadone Treatment: Impact on Arrests
Overview
Authors
Affiliations
Aims: This study examines the frequency and severity of arrest charges among heroin addicts randomly assigned to either interim methadone (IM) maintenance or to remain on a waiting list for methadone treatment. It was hypothesized that IM participants would have a: (1) lower number of arrests at 6 and 12 months and (2) lower mean crime severity scores at 6 and 12 months post-baseline.
Methods: Available official arrest data were obtained for all 319 study participants for a period of 2 years before and after study enrollment. Crime severity ratings of charges were made using an established measure of crime severity.
Findings: Participants randomly assigned to IM as compared to those on a waiting list had a significant reduction in number of arrests at 6 but not at 12 months from study enrollment. There were no significant differences in whether participants were arrested for a more severe crime but frequency of severe crime was relatively low in both groups. Additional post hoc analyses based on whether participants were in methadone treatment at 4 and 10 months after original random assignment to treatment condition revealed that those participants not in treatment at these follow-up assessment points were significantly more likely to be arrested and to have a higher mean crime severity rating at 12 and 24 months post-baseline assessment.
Conclusions: IM as compared to the waiting list condition, had a significant reduction in number of officially recorded arrests from baseline to 6 months post-baseline. Those who were enrolled in methadone treatment at the 4- and 10-month follow-up assessment, regardless of initial assignment, had fewer arrests at 12 and 24 months post-baseline.
A trial of implementation facilitation to increase timely admission to methadone treatment.
Gryczynski J, Mitchell S, Whitter M, Fuller D, Mitchell M, Edelman E J Subst Use Addict Treat. 2024; 162:209375.
PMID: 38642889 PMC: 11197887. DOI: 10.1016/j.josat.2024.209375.
Sigmon S, Peck K, Batchelder S, Badger G, Heil S, Higgins S JAMA Netw Open. 2023; 6(9):e2331910.
PMID: 37755833 PMC: 10534272. DOI: 10.1001/jamanetworkopen.2023.31910.
Interim opioid agonist treatment for opioid addiction: a systematic review.
Jofra L, Puig T, Sola I, Trujols J Harm Reduct J. 2022; 19(1):7.
PMID: 35090475 PMC: 8800211. DOI: 10.1186/s12954-022-00592-x.
Interim methadone - Effective but underutilized: A scoping review.
McCarty D, Chan B, Bougatsos C, Grusing S, Chou R Drug Alcohol Depend. 2021; 225:108766.
PMID: 34051546 PMC: 11833806. DOI: 10.1016/j.drugalcdep.2021.108766.
Within-subject evaluation of interim buprenorphine treatment during waitlist delays.
Oleskowicz T, Ochalek T, Peck K, Badger G, Sigmon S Drug Alcohol Depend. 2021; 220:108532.
PMID: 33508690 PMC: 8148627. DOI: 10.1016/j.drugalcdep.2021.108532.